Professional Summary
Professional Overview
Johnson Lau is an accomplished business leader with extensive experience in the pharmaceutical and biotechnology industries. As the Chairman and CEO of Athenex, he oversees the strategic direction and operations of the company, a global biopharmaceutical organization focused on the development and commercialization of novel therapies for cancer and other serious medical conditions.
Experience Summary
Current Role
As the Chairman and CEO of Athenex since 2003, Johnson Lau has been instrumental in the company's growth and success. Under his leadership, Athenex has become a global leader in the development of innovative cancer treatments, with a robust pipeline of drug candidates in various stages of clinical development. Lau's strategic vision and hands-on management have enabled Athenex to make significant advancements in its research and development efforts, leading to the successful completion of multiple clinical trials and the regulatory approval of several of the company's products.
Career Progression
Prior to his role at Athenex, Lau served as the Chairman of XenoBiotic Laboratories from 2007 to 2014, where he oversaw the company's expansion and helped to establish it as a leading provider of specialized drug testing and analytical services. Lau's extensive industry experience and proven track record of leadership have also led to his appointment as a Board Member at AiViva Biopharma since 2015 and a Member of the Board at Avalon Biomedical Management since 2012.
Academic Background
Lau holds a Ph.D. in Pharmaceutical Sciences from the University of California, San Francisco, where he specialized in drug formulation and delivery. His academic achievements and research contributions have earned him recognition within the scientific community and have contributed to his deep understanding of the complex challenges facing the pharmaceutical industry.
Areas of Expertise
Lau's areas of expertise include strategic planning, operations management, and product development in the pharmaceutical and biotechnology sectors. He has a proven ability to lead cross-functional teams, navigate complex regulatory environments, and drive innovation to address unmet medical needs. Lau's strong technical background and business acumen have been instrumental in his success in guiding Athenex's growth and positioning the company as a leader in the global oncology market.
Professional Impact
Under Lau's leadership, Athenex has achieved significant milestones, including the successful completion of multiple clinical trials, the regulatory approval of several of the company's products, and the expansion of its global presence. Lau's industry contributions and thought leadership have also been recognized through his board memberships and his active involvement in various industry organizations and events.
Conclusion
With his extensive experience, deep industry knowledge, and proven track record of success, Johnson Lau is well-positioned to continue driving Athenex's growth and leading the company's efforts to develop and commercialize innovative cancer treatments that improve patient outcomes and address unmet medical needs worldwide.
